This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
MyBioSource
product type :
ELISA/assay
product name :
Human Sclerostin ELISA Kit
catalog :
MBS760266
quantity :
48-Strip-Wells
price :
300 USD
product information
catalog number :
MBS760266
products type :
ELISA Kit
products full name :
Human Sclerostin ELISA Kit
products short name :
[Sclerostin]
products name syn :
[SOST (Sclerostin)/VBCHsclerosteosis]
other names :
[sclerostin; Sclerostin; sclerostin; sclerostin]
products gene name :
[SOST]
other gene names :
[SOST; SOST; CDD; VBCH; SOST1]
uniprot entry name :
SOST_HUMAN
reactivity :
Human
sequence length :
213
specificity :
This assay has high sensitivity and excellent specificity for detection of SOS1. No significant cross-reactivity or interference between SOS1 and analogues was observed.
storage stability :
Store at 4 degree C if kit is to be used within 1 week. Stable for 6 months (if micro ELISA Plate, Lyophilized Standard and Concentrated Biotinylated Detection Protein stored at-20 degree C. Other components at 2-8 degree C). Stable for 12 months (if the entire kit is stored at-20 degree C).
image1 heading :
Typical Testing Data/Standard Curve (for reference only)
other info1 :
Samples: Serum, Plasma, Tissue Homogenates And Other Biological Fluids. Assay Type: Sandwich. Detection Range: 0.156-10ng/ml. Sensitivity: <0.094ng/ml
other info2 :
Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level SOS1 were tested 20 times on one plate, respectively. Intra-Assay: CV<8%. Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level SOS1 were tested on 3 different plates, 8 replicates in each plate. CV (%) = SD/meanX100. Inter-Assay: CV<10%
products description :
Principle of the Assay: This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti-SOS1 antibody was pre-coated onto 96-well plates. And the biotin conjugated anti-SOS1 antibody was used as detection antibodies. The standards, test samples and biotin conjugated detection antibody were added to the wells subsequently, and washed with wash buffer. HRP-Streptavidin was added and unbound conjugates were washed away with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the SOS1 amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of SOS1 can be calculated.
ncbi gi num :
13376846
ncbi acc num :
NP_079513.1
ncbi gb acc num :
NM_025237.2
ncbi mol weight :
24,264 Da
ncbi pathways :
Negative Regulation Of TCF-dependent Signaling By WNT Ligand Antagonists Pathway (1269608); Signal Transduction Pathway (1269379); Signaling By Wnt Pathway (1269594); TCF Dependent Signaling In Response To WNT Pathway (1269599); Wnt Signaling Pathway (83061); Wnt Signaling Pathway (471)
ncbi summary :
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]
uniprot summary :
SOST: Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. Defects in SOST are the cause of sclerosteosis type 1 (SOST1). An autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. Defects in SOST are a cause of van Buchem disease (VBCH). An autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated. A 52 kb deletion downstream of SOST results in SOST transcription suppression causing van Buchem disease. Defects in SOST are a cause of craniodiaphyseal dysplasia autosomal dominant (CDD). A severe bone dysplasia characterized by massive generalized hyperostosis and sclerosis, especially involving the skull and facial bones. The sclerosis is so severe that the resulting facial distortion is referred to as 'leontiasis ossea' (leonine faces) and the bone deposition results in progressive stenosis of craniofacial foramina. Respiratory obstruction due to choanal stenosis compromises the clinical outcomes of affected patients. Heterozygous mutations located in the secretion signal of the SOST gene prevent sclerostin secretion and can be responsible for craniodiaphyseal dysplasia. Belongs to the sclerostin family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 17q11.2. Cellular Component: extracellular matrix; extracellular region; extracellular space; Golgi apparatus; proteinaceous extracellular matrix. Molecular Function: heparin binding; protein binding; transcription factor binding. Biological Process: negative regulation of BMP signaling pathway; negative regulation of ossification; negative regulation of protein complex assembly; ossification; positive regulation of transcription, DNA-dependent; response to mechanical stimulus; Wnt receptor signaling pathway. Disease: Craniodiaphyseal Dysplasia, Autosomal Dominant; Hyperostosis Corticalis Generalisata; Sclerosteosis 1
size1 :
48-Strip-Wells
price1 :
300 USD
size2 :
96-Strip-Wells
price2 :
415
size3 :
5x96-Strip-Wells
price3 :
1825
size4 :
10x96-Strip-Wells
price4 :
3425
company information
MyBioSource
P.O. Box 153308
San Diego, CA 92195-3308
sales@mybiosource.com
https://www.mybiosource.com
1-888-627-0165
headquarters: USA
MyBioSource, LLC was orginally founded in Vancouver by three enthusiastic scientists who are passionate about providing the world with the best reagents available. Together, they form a company with a big vision known as MyBioSource. MyBioSource is now located in San Diego, California, USA.

"MyBioSource's number 1 vision is to be the world's number 1 quality reagents provider."

Our goal is to provide researchers, scientists and customers alike with a one-stop-shop for all of their reagents needs, whether it is monoclonal antibody, polyclonal antibody, recombinant protein, peptide, etc...

"MyBioSource offers the best products at unbeatable prices."

Please spend a few minutes to browse our online catalogs and see the wide range of products available. We ship our products through our shipping/distribution facility in San Diego, California, USA.

Would you like to receive email and e-newsletter from MyBioSource about new products, special offers and events? Please click here to join our Mailing List!